SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•11/11/2026•16:05 ET
0
Key Highlights
- ➤Net revenue $635,000, up 247% year over year, driven by QUELIMMUNE adoption
- ➤NEUTRALIZE-AKI trial reached 251 of 339 patients, nearly 75% enrollment
- ➤Net loss widened to $4.5 million, or $1.03 per share, from $3.5 million
- ➤Cash fell to $4.0 million at September 30, excluding $3.3 million October warrant proceeds
- ➤SAVE Registry data showed statistically significant higher survival for QUELIMMUNE-treated pediatric patients
Expert Statements
Eric Schlorff, CEO of SeaStar Medical
“The strength of the QUELIMMUNE therapy adoption in this ultra-rare pediatric AKI market provides great promise for our pipeline indications.”
Eric Schlorff, CEO of SeaStar Medical
“And we continue to build momentum in educating the critical care pediatric health care community. In addition to several medical meeting presentations by Dr. Kevin Chung, our CMO, we have already begun sharing with critical care professionals the statistically significant higher survival in QUELIMMUNE-treated patients that was presented at the late-breaking presentation at ASN Kidney Week 2026.”
Eric Schlorff, CEO of SeaStar Medical
“The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, and we have already submitted the first module of the premarket approval application to the FDA in hopes that our modular submission will speed this potential approval. Our Breakthrough Device Designation for this indication will also enable a priority review once we submit the final module with the NEUTRALIZE-AKI pivotal trial results, provided a positive outcome in the trial.”
Continued adoption of the QUELIMMUNE(®) therapy yielded 247% increase in net revenue compared to the third quarter of 2025
Achieved nearly 75% enrollment in the NEUTRALIZE-AKI pivotal clinical trial in adult patients with acute kidney injury (AKI) receiving CRRT
Get started
Create a free account to read the full story.